Dxc Technology Company
$3.16B- Market cap
- $1.86B
- Debt
- +$3.03B
- Cash
- −$1.74B
Capital structure 38% equity / 62% debt · EV / Revenue 0.25x · EV / EBITDA 1.68x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: DXC stock price at discount vs EVH $11.66 current versus $20.60 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EVH's multiple
Implied fair value · at DXC's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXC FY 2026 (ended Mar 31, 2026) · EVH FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 38% equity / 62% debt · EV / Revenue 0.25x · EV / EBITDA 1.68x
Capital structure 33% equity / 67% debt · EV / Revenue 0.70x
DXC carries the larger enterprise value at $3.16B against $1.31B; DXC trades on the lower EV / Revenue multiple (0.25x vs 0.70x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DXC TECHNOLOGY COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Evolent Health, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.03x
2.34x
Net debt / EBITDA
Leverage against operating earnings
0.69x
-2.11x
Cash and equivalents
Liquid reserves on the balance sheet
$1.74B
$151.86M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
DXC vs ACN
INTERNATIONAL BUSINESS MACHINES CORP
DXC vs IBM
COGNIZANT TECHNOLOGY SOLUTIONS CORP
DXC vs CTSH
EPAM Systems, Inc.
DXC vs EPAM
Genpact LTD
DXC vs G
UNISYS CORP
DXC vs UIS
Cigna Group
DXC vs CI
MOLINA HEALTHCARE, INC.
DXC vs MOH
Teladoc Health, Inc.
DXC vs TDOC
CLOVER HEALTH INVESTMENTS, CORP. /DE
DXC vs CLOV
UNITEDHEALTH GROUP INC
DXC vs UNH
$3.03B
$970.54M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.